EUCTR2021-003659-40-FR进行中（未招募）1 期
A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent [...]
- •2. At least 18 years of age.
- •3. A confirmed GBM diagnosis must be based on local review of tumor tissue from the initial biopsy, surgery, or re-resection. A formal pathology report confirming GBM is acceptable. It is not a requirement for slides to be sent to a central reviewer.
- •4. Recurrent GBM as evaluated by RANO criteria, confirmed by central review, as follows: Measurable disease is required with documented unequivocal evidence of tumor recurrence or progression following prior therapy (ie, 25% increase in the sum of the products of
- •perpendicular diameters of the contrast-enhancing lesions while on stable or increasing doses of corticosteroids; however, these changes should not be due to changes in the dose of corticosteroids) as documented by the investigator.
- •5. The tumor is localized supratentorially.
- •6. The lesion (or sum of lesions) does not exceed 50 cm3 in volume.
- •7. MGMT methylation status must be available; results of routinely used methods for MGMT methylation testing (eg, methylation-specific polymerase chain reaction or quantitative polymerase chain reaction) are acceptable.
- •8. No more than 1 prior line of treatment (eg, surgery followed by radiation with concomitant chemotherapy, followed by adjuvant chemotherapy is considered as 1 line of treatment). A second debulking surgery during the first line treatment is acceptable. In addition, treatment with tumor treating fields (TTFields; Optune?) is acceptable if provided as first line therapy.
- •9. Recovery from toxicity/side effects of all prior therapy to Grade 1 or less, subject to the investigator’s discretion, except for alopecia; the following time intervals from previous treatments are required to be eligible:
- •a. 12 weeks from the completion of radiation (to reduce risk of pseudoprogression), unless progression is confirmed by biopsy
- •b. 4 weeks from the end of any previous of chemotherapy or 6 weeks after the end of treatment with nitrosoureas
- •c. 4 weeks from the end of any TTFields treatment
- •d. 4 weeks from any major surgery (maximal debulking surgery, either gross total resection or partial resection) or significant traumatic injury, and any surgery incisions or wounds must be completely healed
- •10. A stable or decreasing dose of corticosteroids (or none) for brain edema for at least 5 days prior to baseline MRI and enrollment in the study to document disease progression such that changes in the MRI are not related to the use of corticosteroids.
- •11. Immunosuppressive therapies allowed include the use of topical, inhalational, ophthalmic or intra-articular glucocorticoids, or the use of physiologic replacement doses of glucocorticoids.
- •12. Eligible for chemotherapy based on adequate bone marrow function and organ function within 2 weeks of study treatment as defined by the following laboratory guidelines, subject to the investigator’s discretion:
- •a. Hematopoietic function: total white blood cell (WBC) count =3000/mm³, absolute neutrophil count (ANC) =1500/mm³, platelet count =75,000/mm³, hemoglobin =10 g/dL
- •b. Hepatic function: bilirubin =1.5 × × the upper limit of normal (ULN) (excluding Gilberts Syndrome, for which bilirubin must be =4 × ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 × ULN, and alkaline phosphatase =2.5 × ULN
- •c. Renal function: serum creatinine =1.5 × ULN or for patients with creatinine levels above the ULN, estimated creatinine clearance of =60 mL/min, calculated using the Cockcroft
排除标准
- •1. Unable or not willing to comply with the protocol regulations.
- •2. Any additional concurrent radiation therapy or chemotherapy (including but not limited to TMZ) for recurrent or progressive GBM after a first line treatment.
- •3. Prior treatment with bevacizumab.
- •4. Prior treatment with lomustine.
- •5. Screening MRI showing a mass effect defined as significant compression of the ventricular system and/or a midline shift (=10 mm)34 confirmed by central MRI review.
- •6. Any condition (medical, social, psychological) that would prevent adequate information and follow-up, including but not limited to clinically relevant psychiatric disorders, legal incapacity, dementia or altered mental status.
- •7. Presence of poorly controlled seizures, defined as occurring despite SOC or requiring hospitalization.
- •8. Prior anthracycline cumulative dose more than 550 mg/m2.
- •9. Heart disease:
- •a. LVEF <50%
- •b. Unstable angina
- •c. CHF with New York Heart Association (NYHA) classification of 3 or 4
- •d. Patients with baseline QT/QTc interval >480 msec, a history of additional risk factors for torsades de pointes (TdP) (eg, heart failure, hypokalemia, family history of long QT syndrome) and using concomitant medications that significantly prolong the QT/QTc interval
- •e. History of myocardial infarction within 12 months of enrollment
- •10. Uncontrolled hypertension (systolic blood pressure [BP] >150 mmHg and/or diastolic BP >100 mmHg).
- •11. Known to be positive for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV), human immunodeficiency virus (HIV), COVID-19 (currently positive at time of screening), or any other acute viral, bacterial, or fungal infection (testing not required unless symptomatic or suspected disease).
- •12. Patients with any other uncontrolled intercurrent medical conditions, including but not limited to diabetes mellitus or chronic obstructive pulmonary disease that have not been well controlled by medical management over the prior 3 months are ineligible unless approved by the sponsor.
研究者
相似试验
招募中
2 期
A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme2024-517660-27-00Cns Pharmaceuticals Inc.126
进行中（未招募）
不适用
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsMultiple Sclerosis (MS)MedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-004622-29-ITBiogen Idec Research Limited540
进行中（未招募）
1 期
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsMultiple Sclerosis (MS)MedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-004622-29-ESBiogen Idec Research Limited540
进行中（未招募）
1 期
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsMultiple Sclerosis (MS)MedDRA version: 19.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-004622-29-DKBiogen Idec Research Limited540
进行中（未招募）
1 期
Impact of Natalizumab versus Fingolimod on Central Nervous System (CNS) Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis (RRMS) SubjectsEUCTR2013-004622-29-DEBiogen Idec Research Limited540